- Home
- NUVL vs WING Comparison
NUVL vs WING Comparison
Compare NUVL & WING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- WING
- Stock Information
- Founded
- NUVL 2017
- WING 1994
- Country
- NUVL United States
- WING United States
- Employees
- NUVL N/A
- WING N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- WING Restaurants
- Sector
- NUVL Health Care
- WING Consumer Discretionary
- Exchange
- NUVL Nasdaq
- WING Nasdaq
- Market Cap
- NUVL 6.5B
- WING 6.7B
- IPO Year
- NUVL 2021
- WING 2015
- Fundamental
- Price
- NUVL $104.59
- WING $209.21
- Analyst Decision
- NUVL Strong Buy
- WING Strong Buy
- Analyst Count
- NUVL 11
- WING 21
- Target Price
- NUVL $121.45
- WING $356.50
- AVG Volume (30 Days)
- NUVL 498.8K
- WING 712.2K
- Earning Date
- NUVL 11-10-2025
- WING 11-04-2025
- Dividend Yield
- NUVL N/A
- WING 0.49%
- EPS Growth
- NUVL N/A
- WING 86.15
- EPS
- NUVL N/A
- WING 5.96
- Revenue
- NUVL N/A
- WING $669,742,000.00
- Revenue This Year
- NUVL N/A
- WING $18.65
- Revenue Next Year
- NUVL N/A
- WING $19.27
- P/E Ratio
- NUVL N/A
- WING $40.73
- Revenue Growth
- NUVL N/A
- WING 22.74
- 52 Week Low
- NUVL $55.54
- WING $204.00
- 52 Week High
- NUVL $103.69
- WING $388.14
- Technical
- Relative Strength Index (RSI)
- NUVL 71.49
- WING 25.80
- Support Level
- NUVL $90.00
- WING $251.43
- Resistance Level
- NUVL $99.94
- WING $261.32
- Average True Range (ATR)
- NUVL 4.59
- WING 10.14
- MACD
- NUVL 1.10
- WING -1.83
- Stochastic Oscillator
- NUVL 100.00
- WING 0.02
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About WING Wingstop Inc.
Founded in 1994 in Garland, Texas, Wingstop is a restaurant operator specializing in indulgent bone-in and boneless chicken wings, chicken tenders, fries, and, recently, chicken sandwiches. The firm's footprint has grown quickly since its inception, expanding to 2,818 global stores at the end of the second quarter of 2025. With a 98% franchised model, Wingstop generates the lion's share of its revenue from franchise royalties and advertising fees, with the remainder derived from a small footprint of company-owned stores.